{"gene":"BTG2","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":1996,"finding":"BTG2/TIS21 interacts physically with PRMT1 (protein-arginine N-methyltransferase 1), and GST-TIS21 fusion protein modulates endogenous PRMT1 methyltransferase activity on protein substrates, suggesting BTG2 acts as a regulatory subunit of PRMT1.","method":"Yeast two-hybrid screening, GST pulldown, in vitro methyltransferase activity assay with cell extracts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — yeast two-hybrid plus GST pulldown plus direct enzymatic activity assay, replicated across BTG1 and TIS21; foundational biochemical study","pmids":["8663146"],"is_preprint":false},{"year":1996,"finding":"BTG2 expression is induced by p53 in response to DNA damage and its overexpression inhibits cell proliferation, placing BTG2 as a p53-dependent component of the DNA damage cellular response pathway.","method":"p53-inducible gene identification, transfection overexpression with proliferation/cell-cycle readouts","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — p53-dependent transcriptional induction demonstrated experimentally; antiproliferative function confirmed by overexpression; widely replicated by subsequent studies","pmids":["8944033"],"is_preprint":false},{"year":1998,"finding":"BTG1 and BTG2 physically interact with mCaf1 (mouse CCR4-associated factor 1) in vitro and in vivo, and the conserved Box B domain of BTG proteins is essential for the BTG–mCaf1 interaction, suggesting BTG2 participates in transcriptional regulation via the CCR4 complex.","method":"Yeast two-hybrid screening, GST pulldown (in vitro binding assay), co-immunoprecipitation in HeLa cells, transient transfection, Box B deletion mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal in vitro and in vivo binding confirmed; domain mapped by deletion mutagenesis; orthogonal methods in single rigorous study","pmids":["9712883"],"is_preprint":false},{"year":1998,"finding":"Overexpression of TIS21 in 293 cells reduces synthesis of cyclin E and CDK4 proteins and decreases cyclin E-associated CDK kinase activity, causing G1 accumulation, identifying cyclin E and CDK4 downregulation as a mechanism of TIS21-induced G1 arrest.","method":"Stable transfection, FACS cell-cycle analysis (double thymidine block), western blot for cyclin E and CDK4, cyclin E-associated kinase activity assay","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean stable-expression system with biochemical readouts; single lab, two orthogonal methods","pmids":["9766435"],"is_preprint":false},{"year":2001,"finding":"BTG1 and BTG2 interact with both hCAF1 and hPOP2 (human paralogs of the yeast CCR4-associated factors) in vitro and in vivo, and LXXLL nuclear receptor box motifs in BTG1/BTG2 are involved in regulating estrogen receptor alpha (ERα)-mediated transcription, demonstrating that BTG2 can modulate ERα function through the CCR4-like complex.","method":"Co-immunoprecipitation, GST pulldown, interaction domain mapping, transient transfection reporter assays for ERα transcriptional activity","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional reporter assays; multiple orthogonal methods in one study","pmids":["11136725"],"is_preprint":false},{"year":2001,"finding":"TIS21/BTG2 protein interacts physically with rPICK1 (a PKCα-binding protein) via PICK1's PDZ domain, and this interaction modulates PKC-mediated phosphorylation of TIS21, suggesting a role for BTG2 in PKC signal transduction.","method":"Yeast two-hybrid, GST pulldown with in vitro translated TIS21, co-immunoprecipitation from NIH 3T3 cells, PDZ domain deletion mutagenesis, in vitro PKC phosphorylation assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding confirmed in vitro and in vivo; domain mapped; single lab","pmids":["11237868"],"is_preprint":false},{"year":2003,"finding":"BTG2 interacts in vivo with hCCR4 protein via hCAF1 and hPOP2 within mammalian CCR4-NOT complexes of ~650 kDa, ~1 MDa, and ~1.9 MDa; hCAF1 cellular localization changes as cells progress from quiescence to S phase, suggesting distinct CCR4 complexes mediate different BTG2 functions at different cell-cycle stages.","method":"Immunoprecipitation, gel filtration chromatography, cell-cycle fractionation, transient transfection reporter assays for ERα activity","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gel filtration plus Co-IP establish complex composition and size; single lab","pmids":["12771185"],"is_preprint":false},{"year":2004,"finding":"BTG2 physically interacts with BMP-activated Smad proteins (Smad1/Smad8) and enhances BMP transcriptional signaling, as demonstrated biochemically and by the vertebral patterning phenotype in Btg2-null mice which phenocopies reduced BMP signaling.","method":"Btg2-knockout mouse generation, vertebral phenotype analysis, co-immunoprecipitation/pulldown of Btg2 with Smad1/Smad8, transcriptional reporter assays for BMP signaling","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic knockout phenotype plus biochemical interaction evidence; functional epistasis with BMP pathway; multiple orthogonal approaches in single study","pmids":["15542835"],"is_preprint":false},{"year":2004,"finding":"BTG2 expression is induced by NF-κB activation in breast cancer cells, and BTG2 inhibits breast cancer cell growth by arresting cells in G1 through suppression of cyclin D1 expression; this effect is reversed by cyclin D1 re-expression.","method":"NF-κB stimulation assays, BTG2 ectopic expression in breast cancer cells, growth arrest assays, rescue experiment with cyclin D1 overexpression","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional rescue experiment with cyclin D1 directly links BTG2 to cyclin D1-dependent G1 arrest; single lab","pmids":["15378000"],"is_preprint":false},{"year":2004,"finding":"TIS21/BTG2 is expressed through a PKC-delta signaling pathway and inhibits cyclin B1-Cdc2 binding and kinase activity in vivo (G2/M inhibition), independent of p53; TIS21 also stabilizes cyclin A and cyclin B1 by preventing their degradation.","method":"PKC inhibitor pharmacology, dnPKC-delta transfection, nocodazole synchronization, co-immunoprecipitation of cyclin B1-Cdc2, in vivo kinase assay, FACS analysis","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase activity assay plus Co-IP plus pharmacological epistasis; single lab, multiple methods","pmids":["15302583"],"is_preprint":false},{"year":2005,"finding":"p-Erk1/2 phosphorylates TIS21 at Ser147; this phosphorylation promotes binding of TIS21 to Pin1 (prolyl isomerase), which causes Pin1 relocalization to the cytoplasm and subsequent mitochondrial depolarization and cell death. The P148A mutation abolishes Pin1 binding.","method":"In vitro kinase assay with p-Erk1/2 and p-p38, site-directed mutagenesis (P148A), co-immunoprecipitation, shRNAi knockdown of TIS21, confocal microscopy of Pin1 localization, flow cytometry (JC-1 mitochondrial membrane potential)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, mutagenesis, and functional cellular readouts (mitochondrial depolarization, cell death) all in one study; single lab but multiple orthogonal methods","pmids":["15788397"],"is_preprint":false},{"year":2006,"finding":"BTG2 enhances PRMT1 participation in the RARα transcriptional complex on the RARβ promoter, increases histone H4 arginine methylation at this gene in the absence of retinoic acid, and upon retinoic acid treatment BTG2 and PRMT1 dissociate from RARα, enabling histone H4 demethylation and acetylation that prime differentiation.","method":"Co-immunoprecipitation of RARα complex, chromatin immunoprecipitation (ChIP) for H4 arginine methylation and acetylation at RARβ promoter, overexpression in myeloid leukemia cells and CD34+ progenitors, differentiation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP plus Co-IP demonstrate mechanism at specific promoter; functional differentiation readout; single lab but multiple orthogonal methods","pmids":["16782888"],"is_preprint":false},{"year":2008,"finding":"BTG2 is a general activator of mRNA deadenylation: it stimulates poly(A) tail shortening of all transcripts tested through its interaction with the CAF1/CCR4 deadenylase complex; CAF1 nuclease activity is required for efficient deadenylation, and both CAF1 and CCR4 deadenylase activities are required for BTG2-induced poly(A) degradation.","method":"In vitro deadenylation assays with reporter mRNAs, CAF1 nuclease-dead mutants, BTG2 overexpression in mammalian cells, mRNA half-life measurements","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of deadenylation plus mutagenesis of catalytic residues plus cellular mRNA decay assays; multiple orthogonal methods","pmids":["18337750"],"is_preprint":false},{"year":2008,"finding":"Crystal structures of human BTG2 and mouse TIS21 were solved to 2.3 Å and 2.2 Å resolution, respectively; the structures reveal a putative CAF1 binding site; structure-guided mutagenesis of BTG2 at this site reduces CAF1 deadenylase activity, demonstrating that BTG2 suppresses CAF1 deadenylase activity through direct structural interaction.","method":"X-ray crystallography, in vitro CAF1 deadenylase activity assay with wild-type and interface mutant BTG2","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus structure-guided mutagenesis plus direct enzymatic assay; multiple orthogonal methods in single study","pmids":["18974182"],"is_preprint":false},{"year":2008,"finding":"TIS21 inhibits FoxM1 phosphorylation (required for FoxM1 activation) by reducing cyclin B1-CDK1 kinase activity, thereby disrupting the FoxM1-cyclin B1 regulatory loop; this was confirmed by in vitro kinase assay, FoxM1 mutant analyses, and in vivo reciprocal expression studies.","method":"In vitro kinase assay, FoxM1 phosphorylation mutant analysis, TIS21 forced expression in Huh7 cells, TIS21-null mouse embryonic fibroblasts, DEN-induced hepatocarcinoma model","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro kinase assay with mutagenesis, complemented by in vivo genetic model; single lab but rigorous multi-method approach","pmids":["18393292"],"is_preprint":false},{"year":2008,"finding":"PRMT1 plays a pivotal role in neurite outgrowth of Neuro2a cells, and BTG2 (a PRMT1 binding partner) depletion downregulates nuclear arginine methylation and inhibits neurite outgrowth, indicating the BTG2-PRMT1 interaction is functionally required for arginine methylation-dependent neuronal differentiation.","method":"shRNA knockdown of PRMT1 and Btg2 in Neuro2a cells, immunofluorescence for neurite morphology, western blot for methylarginine marks","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular phenotype; single lab, single method per protein","pmids":["18773938"],"is_preprint":false},{"year":2009,"finding":"TIS21 promotes repair of DNA double-strand breaks by increasing PRMT1-dependent arginine methylation of Mre11, activating Mre11 nuclease activity; TIS21 also blocks the ATM→Chk2(T68)→p53(S20) damage signal cascade while not affecting p53(S15) phosphorylation, thereby reducing apoptosis after etoposide treatment.","method":"Adenoviral TIS21 transduction of Huh7 cells, γH2AX foci clearance assay, Comet assay, immunoprecipitation and radiolabeling for Mre11 methylation, PRMT1 in vitro activity assay, western blot for Chk2 and p53 phosphorylation, TIS21-null MEFs","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct enzymatic assay (PRMT1, Mre11 methylation), γH2AX foci, Comet assay, phospho-signaling, and genetic KO MEFs; multiple orthogonal methods","pmids":["23089312"],"is_preprint":false},{"year":2009,"finding":"BTG2 depletion in human fibroblasts extends cellular lifespan, and ectopic BTG2 induces senescence independently of p53; BTG2 is stabilized by telomere dysfunction and serum-dependently binds and relocalizes Pin1 (prolyl isomerase), and Pin1 inhibition leads to senescence while ectopic Pin1 rescues BTG2-induced senescence.","method":"siRNA depletion, ectopic overexpression, co-immunoprecipitation of BTG2-Pin1, cellular lifespan/senescence assays, Pin1 overexpression rescue experiment in late-passage fibroblasts","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (rescue by Pin1 OE) plus Co-IP; single lab, two orthogonal approaches","pmids":["20569234"],"is_preprint":false},{"year":2009,"finding":"PC3/Tis21 deletion causes increased proliferation of adult dentate gyrus progenitor cells and arrest of their terminal differentiation, with accumulation of undifferentiated postmitotic neurons and reduced terminally differentiated neurons; PC3/Tis21 associates with the Id3 promoter and negatively regulates Id3 expression, placing Tis21 upstream of Id3 in the differentiation cascade.","method":"PC3/Tis21-null mouse analysis, BrdU/NeuN neurogenesis markers, ChIP for Tis21 at Id3 promoter, immunofluorescence, Morris water maze behavioral assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined cellular phenotype, ChIP for direct promoter binding, behavioral functional readout; multiple orthogonal methods","pmids":["20020054"],"is_preprint":false},{"year":2009,"finding":"SKP2 (SCF ubiquitin ligase subunit) binds to the C-terminus of TIS21 via its leucine-rich repeat (LRR) domain and promotes polyubiquitination and proteasomal degradation of TIS21; FoxM1 regulates Skp2 expression and thereby controls TIS21 protein stability.","method":"Co-immunoprecipitation, deletion mutagenesis of Skp2 (ΔLRR) and TIS21 (ΔC), ubiquitination assays, cycloheximide chase (protein half-life), siRNA knockdown of Skp2, FoxM1 co-expression","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus deletion mutagenesis plus ubiquitination assay; single lab","pmids":["19615363"],"is_preprint":false},{"year":2010,"finding":"TIS21/BTG2 inhibits invadopodia formation in MDA-MB-231 breast cancer cells by downregulating intracellular reactive oxygen species (ROS) levels, with consequent F-actin remodeling; this was confirmed in TIS21-null MEFs which show enhanced invadopodia.","method":"Adenoviral TIS21 transduction, invadopodia/gelatin degradation assay, Matrigel invasion assay, FACS-based ROS measurement (DCFH-DA), TIS21-null MEF controls","journal":"Journal of cancer research and clinical oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss- and gain-of-function with defined cellular phenotype; genetic KO confirmation; single lab","pmids":["23907596"],"is_preprint":false},{"year":2012,"finding":"BTG2 stimulates antioxidant gene expression (catalase, SOD1, SOD2) through direct interaction with the transcription factor NFE2L2 (Nrf2); BTG2 is detectable at the antioxidant response element (ARE) of NFE2L2-responsive genes by ChIP; the conserved Box B domain is required for BTG2-NFE2L2 interaction, protection against oxidative stress, and antioxidant gene upregulation.","method":"Co-immunoprecipitation for BTG2-NFE2L2 interaction, ChIP at ARE elements, cell viability assays under H2O2 stress, siRNA knockdown of NFE2L2, Box B deletion mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct Co-IP, ChIP at endogenous promoters, domain mutagenesis, functional rescue; multiple orthogonal methods","pmids":["22493435"],"is_preprint":false},{"year":2012,"finding":"BTG2 loss shifts normal prostate basal cells toward luminal marker expression and induces EMT traits; miR-21 overexpression suppresses BTG2 levels and promotes luminal/EMT phenotype; derepression of BTG2 via a decoy 3'-UTR construct reduces luminal and EMT markers in prostate tumor cells and abrogates orthotopic tumor growth.","method":"BTG2 knockdown/lentiviral 3'-UTR decoy in prostate cell lines, immunofluorescence for luminal/EMT markers, miR-21 overexpression, orthotopic murine model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — decoy 3'-UTR derepression experiment plus in vivo orthotopic model; mechanistic link between BTG2 and EMT; single lab","pmids":["22614007"],"is_preprint":false},{"year":2013,"finding":"TIS21/BTG2 inhibits breast cancer cell invasion through a TIS21-Akt1-Sp1-Nox4 pathway: TIS21 activates Akt1, which reduces Sp1-mediated Nox4 transcription, decreasing Nox4-derived ROS and thereby inhibiting mDia (diaphanous-related formin) expression and F-actin remodeling required for invasion.","method":"RNA interference knockdown of Akt1, adenoviral TIS21 transduction, Nox4 promoter reporter assays, ROS measurement, Matrigel invasion assay, western blot for mDia/actin regulators","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via Akt1 knockdown plus promoter reporter assays plus ROS measurement; single lab, multiple methods","pmids":["25798836"],"is_preprint":false},{"year":2016,"finding":"BTG2 APRO domain directly interacts with the first RRM domain of PABPC1 (cytoplasmic poly(A)-binding protein); PABPC1 RRM1 and BTG2 APRO domains together are sufficient to stimulate CAF1 deadenylase activity in vitro without other CCR4-NOT subunits; this BTG2-PABPC1 interaction is required for BTG2 to control cell proliferation.","method":"In vitro reconstitution of deadenylation assay with purified domains, pulldown/binding assays for APRO-RRM1 interaction, mutagenesis of interaction interface, cell proliferation assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with minimal components, mutagenesis, and functional cellular readout; single lab but multiple orthogonal methods in rigorous study","pmids":["26912148"],"is_preprint":false},{"year":2017,"finding":"BTG2 and PRMT1 form a module in pre-B cells that induces cell-cycle arrest by enabling PRMT1 to methylate CDK4, thereby preventing CDK4-Cyclin D3 complex formation and blocking cell cycle progression; BTG2-PRMT1 also blocks proliferation of BCR-ABL1-transformed pre-B cells in vitro and in vivo.","method":"Co-immunoprecipitation, in vitro methylation assay for CDK4 by PRMT1, CDK4-Cyclin D3 complex pulldown, BTG2/PRMT1 conditional knockout pre-B cells, BCR-ABL1 transformation model in vivo","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct in vitro methylation assay of CDK4 plus Co-IP of CDK4-CyclinD3 complex plus genetic KO, in vivo model; multiple orthogonal methods","pmids":["28628091"],"is_preprint":false},{"year":2020,"finding":"BTG1 and BTG2 (BTG1/2) promote mRNA deadenylation and degradation to maintain T cell quiescence; BTG1/2-deficient T cells show increased global mRNA abundance with longer poly(A) tails and greater mRNA half-lives, reducing the activation threshold; this establishes mRNA deadenylation as the mechanism underlying BTG2-dependent T cell quiescence.","method":"Conditional BTG1/2 double-knockout mice, global mRNA-seq, poly(A) tail length measurement, mRNA half-life assays, T cell proliferation and spontaneous activation assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-KO with genome-wide mRNA abundance and poly(A) tail length measurements; mechanistic link between BTG2, deadenylation, and quiescence replicated in multiple assays","pmids":["32165587"],"is_preprint":false},{"year":2020,"finding":"TRIM6 E3 ubiquitin ligase interacts with TIS21/BTG2, promotes its polyubiquitination at Lys5, and decreases TIS21 protein stability; a TRIM6 catalytic mutant (C15A) fails to ubiquitinate TIS21; TIS21 overexpression reverses TRIM6-driven cell proliferation and suppresses FoxM1/cyclin B1 signaling.","method":"Immunoprecipitation, proteomics, ubiquitination assay with TRIM6 WT and C15A mutant, cycloheximide chase, site-directed mutagenesis of TIS21 (Lys5), TIS21 overexpression rescue assays","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay with E3 catalytic mutant plus Lys5 mutagenesis; single lab, two orthogonal methods","pmids":["31992359"],"is_preprint":false},{"year":2022,"finding":"KIAA1429 (VIRMA, an m6A RNA methyltransferase) mediates m6A modification of BTG2 mRNA; knockdown of KIAA1429 decreases BTG2 mRNA m6A levels, leading to increased YTHDF2 (m6A reader)-dependent BTG2 mRNA stability and elevated BTG2 expression, placing BTG2 regulation downstream of m6A mRNA modification.","method":"MeRIP-seq (methylated RNA immunoprecipitation sequencing), RNA stability assay, KIAA1429 knockdown, transcriptome-seq, m6A dot blot","journal":"Cancer communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeRIP-seq plus RNA stability assay mechanistically link m6A on BTG2 mRNA to YTHDF2-dependent stability; single lab","pmids":["35730068"],"is_preprint":false},{"year":2016,"finding":"Btg2 negatively regulates cardiomyocyte hypertrophy by reducing cytosolic (but not nuclear) RNA levels; Btg2 binds components of mRNA deadenylation complexes as shown by mass spectrometry; Btg2 knockdown enhances cytosolic RNA accumulation under adrenergic stimulation.","method":"Btg2 shRNA knockdown in cardiomyocytes, Myc-mediated hypermetabolic model, single-cell RNA imaging with nascent RNA labeling, ChIP-seq, mass spectrometry of Btg2-associated proteins, cardiomyocyte surface area measurement","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry identifies deadenylation complex partners; shRNA KD with RNA quantification; single lab, multiple methods","pmids":["27346836"],"is_preprint":false},{"year":2023,"finding":"BTG2 promotes podocyte-to-mesenchymal transition (EMT) and FSGS by binding specifically to Smad3 (not Smad2) and enhancing Smad3 signaling; podocyte-specific deletion of Btg2 protects against proteinuria and glomerulosclerosis; a TGF-β/Smad3–Btg2 positive feedback circuit was identified.","method":"Podocyte-specific Btg2 conditional knockout mice, co-immunoprecipitation of Btg2 with Smad2 vs Smad3, Smad3 inhibitor (SIS3) rescue, Btg2 overexpression in cultured MPC5 podocytes, ADR-induced FSGS model","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined phenotype plus Co-IP distinguishing Smad2 vs Smad3 specificity; single lab, two orthogonal methods","pmids":["37749872"],"is_preprint":false},{"year":1994,"finding":"The TIS21/PC3 protein is a non-nuclear, soluble intracellular protein (not secreted and not membrane-associated), as established by immunohistochemistry and subcellular fractionation experiments; the protein is synthesized rapidly after stimulation and is degraded much more rapidly than the related TIS7/PC4 protein.","method":"Pulse-chase metabolic labeling, subcellular fractionation, immunohistochemistry with anti-TIS21 antiserum","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation plus immunohistochemistry; single lab; negative result (no secretion detected) rigorously established","pmids":["8263025"],"is_preprint":false},{"year":2012,"finding":"Tis21 deletion in Patched1 heterozygous mice increases medulloblastoma frequency; genome-wide analysis identified Cxcl3 as a transcriptional target of Tis21; Tis21-null cerebellar granule neuron precursors show downregulated Cxcl3 and defective migration; addition of exogenous Cxcl3 rescues migration defect and reduces hyperplastic lesion area, placing Tis21 upstream of Cxcl3-dependent GCP migration.","method":"Double-KO mouse cross (Tis21-/-; Ptch1+/-), genome-wide gene expression analysis, cerebellar slice migration assay, Cxcl3 protein addition rescue experiment","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo plus rescue experiment with defined molecular target; genome-wide identification of Cxcl3 as Tis21 target; multiple orthogonal approaches","pmids":["23115191"],"is_preprint":false},{"year":2008,"finding":"In TIS21-null mice, p-Erk1/2 preferentially binds Akt (preventing Akt activation), and mTOR is constitutively active; reconstitution of TIS21 inhibits p-Erk1/2-Akt interaction; TIS21 thereby negatively regulates estradiol-stimulated hematopoietic stem cell expansion through this Akt/mTOR axis.","method":"TIS21 knockout mice, co-immunoprecipitation of p-Erk1/2 with Akt, TIS21 reconstitution in MEFs, Erk1 siRNA knockdown, rapamycin treatment, LSK flow cytometry of bone marrow","journal":"Stem cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus reconstitution rescue plus genetic KO; single lab, multiple methods","pmids":["18556508"],"is_preprint":false}],"current_model":"BTG2 (TIS21/PC3) is a multifunctional antiproliferative protein that acts primarily as a transcriptional co-regulator and mRNA decay activator: it binds the CAF1/CCR4-NOT deadenylase complex (via its APRO domain) and simultaneously bridges PABPC1's RRM1 domain to stimulate poly(A) tail shortening and mRNA degradation; it interacts with and modulates PRMT1 arginine methyltransferase activity, directing histone H4 arginine methylation at specific promoters (e.g., RARβ) and CDK4 methylation to block cell cycle progression; it is transcriptionally induced by p53 after DNA damage and by NF-κB under stress; it promotes DNA double-strand break repair by enhancing PRMT1-mediated Mre11 methylation while blocking ATM→Chk2→p53(S20) signaling; its protein stability is controlled by Skp2-mediated polyubiquitination (at Lys5) regulated by FoxM1, and by Erk1/2-dependent phosphorylation at Ser147 that recruits Pin1 to induce mitochondrial depolarization; it enhances BMP/Smad signaling and suppresses cyclin D1, cyclin E, and CDK4 levels to enforce G1 arrest, inhibits cyclin B1-CDK1 activity to cause G2/M arrest, and activates Akt1 to suppress Nox4-ROS-mDia-dependent cancer cell invasion."},"narrative":{"mechanistic_narrative":"BTG2 (TIS21/PC3) is an antiproliferative protein that enforces cell-cycle exit and quiescence through two convergent activities: activation of mRNA deadenylation and regulation of arginine methylation, both deployed downstream of stress and damage signals [PMID:18337750, PMID:23089312, PMID:32165587]. As a deadenylation activator, BTG2 binds the CAF1/CCR4-NOT complex via its conserved Box B/APRO domain and stimulates poly(A) tail shortening of transcripts, a function dissected biochemically and structurally: the BTG2 APRO domain bridges the first RRM domain of PABPC1 to CAF1, and these minimal components are sufficient to stimulate deadenylation and are required for BTG2 to control proliferation [PMID:9712883, PMID:18337750, PMID:18974182, PMID:26912148]. Genetic loss of BTG1/2 in T cells globally lengthens poly(A) tails and stabilizes mRNAs, lowering the activation threshold and establishing deadenylation as the basis of BTG2-dependent quiescence [PMID:32165587]. In parallel, BTG2 is a regulatory partner of the arginine methyltransferase PRMT1, modulating its activity to direct histone H4 arginine methylation at the RARβ promoter, to methylate Mre11 in support of double-strand break repair, and to methylate CDK4 and thereby block CDK4-Cyclin D3 assembly and cell-cycle progression [PMID:8663146, PMID:16782888, PMID:23089312, PMID:28628091]. BTG2 is transcriptionally induced by p53 after DNA damage and by NF-κB, and it imposes G1 arrest by suppressing cyclin E, CDK4, and cyclin D1 and G2/M arrest by inhibiting cyclin B1-CDK1 and disrupting the FoxM1-cyclin B1 loop [PMID:8944033, PMID:9766435, PMID:15378000, PMID:15302583, PMID:18393292]. It additionally couples to differentiation and tissue patterning by enhancing BMP/Smad signaling, regulating adult neurogenesis through Id3 and Cxcl3, and modulating antioxidant responses via NFE2L2; in cancer it suppresses invasion through an Akt1-Sp1-Nox4-ROS axis [PMID:15542835, PMID:20020054, PMID:22493435, PMID:25798836, PMID:23115191]. BTG2 protein stability is set by ubiquitin ligases SKP2 and TRIM6 (the latter targeting Lys5) and by Erk1/2 phosphorylation at Ser147 that recruits Pin1 to drive mitochondrial depolarization and senescence [PMID:15788397, PMID:20569234, PMID:19615363, PMID:31992359].","teleology":[{"year":1994,"claim":"Establishing BTG2/TIS21 as a rapidly synthesized, rapidly turned-over soluble intracellular protein framed it as an immediate-response factor rather than a secreted or membrane signaling molecule.","evidence":"Pulse-chase metabolic labeling, subcellular fractionation, and immunohistochemistry","pmids":["8263025"],"confidence":"Medium","gaps":["Does not define molecular function","Reported as non-nuclear, later studies place it on chromatin and in deadenylation complexes"]},{"year":1996,"claim":"Identification of BTG2 as a p53-induced gene that arrests proliferation, and as a physical modulator of PRMT1 methyltransferase activity, defined its two foundational axes: the DNA-damage response and arginine methylation.","evidence":"p53-inducible gene identification with overexpression readouts; yeast two-hybrid, GST pulldown, and in vitro methyltransferase assays","pmids":["8944033","8663146"],"confidence":"High","gaps":["How PRMT1 modulation connects to antiproliferation not yet defined","Substrate specificity of the BTG2-PRMT1 module unknown"]},{"year":1998,"claim":"Mapping the conserved Box B domain interaction with mCaf1 placed BTG2 in the CCR4 deadenylase complex, while overexpression linked it to downregulation of cyclin E and CDK4 during G1 arrest.","evidence":"Yeast two-hybrid, GST pulldown, Co-IP, Box B deletion mutagenesis; stable transfection with FACS and cyclin/CDK kinase assays","pmids":["9712883","9766435"],"confidence":"High","gaps":["Functional consequence of Caf1 binding not yet tested","Whether cyclin/CDK loss is direct or via mRNA decay unresolved"]},{"year":2001,"claim":"Demonstrating BTG2 binding to hCAF1/hPOP2 and to PICK1, with LXXLL-dependent modulation of ERα transcription, expanded its role to nuclear-receptor transcriptional control and PKC signaling.","evidence":"Co-IP, GST pulldown, domain mapping, ERα reporter assays; PICK1 PDZ-domain mapping and in vitro PKC phosphorylation","pmids":["11136725","11237868"],"confidence":"High","gaps":["Physiological relevance of PICK1 interaction not established","Link between deadenylation complex binding and transcriptional output unclear"]},{"year":2003,"claim":"Showing BTG2 resides in multiple CCR4-NOT complexes of distinct sizes that vary with cell-cycle stage suggested complex composition tunes BTG2 function across the cycle.","evidence":"Immunoprecipitation, gel filtration chromatography, and cell-cycle fractionation","pmids":["12771185"],"confidence":"Medium","gaps":["Functional difference between complex sizes not demonstrated","Mechanism linking hCAF1 relocalization to function unknown"]},{"year":2004,"claim":"Three studies extended BTG2 to developmental and stress signaling: it binds BMP-Smad1/8 to enhance BMP signaling (with a vertebral phenotype in knockouts), is induced by NF-κB to suppress cyclin D1, and inhibits cyclin B1-Cdc2 via a PKCδ pathway independent of p53.","evidence":"Btg2-null mice with Co-IP and BMP reporters; NF-κB stimulation with cyclin D1 rescue; PKC pharmacology, nocodazole synchronization, and in vivo kinase assays","pmids":["15542835","15378000","15302583"],"confidence":"High","gaps":["Whether Smad and cyclin effects share a common biochemical mechanism unresolved","Direct versus indirect control of cyclin levels not separated from mRNA decay activity"]},{"year":2005,"claim":"Discovery that Erk1/2 phosphorylates BTG2 at Ser147 to recruit Pin1 and trigger mitochondrial depolarization defined a post-translational switch converting BTG2 toward cell death.","evidence":"In vitro kinase assay, P148A mutagenesis, Co-IP, shRNA, confocal Pin1 imaging, and JC-1 flow cytometry","pmids":["15788397"],"confidence":"High","gaps":["How cytoplasmic Pin1 relocalization causes depolarization not detailed","Relationship to deadenylation function unknown"]},{"year":2006,"claim":"ChIP evidence that BTG2 brings PRMT1 to the RARα complex and deposits H4 arginine methylation at the RARβ promoter, reversed by retinoic acid, gave a concrete chromatin mechanism for BTG2 in differentiation priming.","evidence":"Co-IP of RARα complex, ChIP for H4 methylation/acetylation, and differentiation assays in myeloid progenitors","pmids":["16782888"],"confidence":"High","gaps":["Genome-wide scope of BTG2-directed H4 methylation unknown","How retinoic acid triggers BTG2/PRMT1 dissociation unresolved"]},{"year":2008,"claim":"A cluster of studies cemented BTG2 as a general deadenylation activator and stability-regulated cell-cycle brake: it stimulates CAF1/CCR4-dependent poly(A) shortening of all transcripts, its crystal structure reveals the CAF1-binding interface, it inhibits FoxM1 by reducing cyclin B1-CDK1 activity, SKP2 targets it for degradation, and its PRMT1 partnership drives neurite outgrowth.","evidence":"In vitro deadenylation with CAF1 nuclease-dead mutants; X-ray crystallography with interface mutagenesis; in vitro kinase/FoxM1 mutant analysis with KO MEFs; Co-IP, ubiquitination and CHX-chase; PRMT1/Btg2 knockdown in Neuro2a","pmids":["18337750","18974182","18393292","19615363","18773938","18556508"],"confidence":"High","gaps":["Whether deadenylation accounts for all antiproliferative phenotypes not fully separated from methylation activity","In vivo target transcripts of BTG2-driven decay not enumerated at this stage"]},{"year":2009,"claim":"BTG2 was shown to promote DSB repair via PRMT1-dependent Mre11 methylation while damping ATM-Chk2-p53(S20) signaling, to drive p53-independent senescence through Pin1, and to control adult neurogenesis through direct repression of Id3.","evidence":"γH2AX/Comet assays with Mre11 methylation and phospho-signaling; senescence assays with Pin1 Co-IP and rescue; PC3/Tis21-null mice with ChIP at Id3 and behavioral readouts","pmids":["23089312","20569234","20020054"],"confidence":"High","gaps":["How BTG2 simultaneously promotes repair and limits damage signaling mechanistically unresolved","Pin1-dependent senescence versus DNA-repair roles not reconciled"]},{"year":2012,"claim":"BTG2 was linked to oxidative-stress defense through direct NFE2L2/Nrf2 interaction and antioxidant gene induction, to EMT suppression via miR-21-regulated prostate phenotype, and to Cxcl3-dependent cerebellar precursor migration and tumor suppression.","evidence":"Co-IP, ChIP at ARE, H2O2 viability with Box B mutagenesis; 3'-UTR decoy with orthotopic model; Tis21/Ptch1 double-KO with Cxcl3 rescue","pmids":["22493435","22614007","23115191"],"confidence":"High","gaps":["Whether antioxidant and decay functions are coupled unknown","Direct versus indirect nature of Cxcl3 regulation not fully resolved"]},{"year":2016,"claim":"Structural-functional reconstitution showed the BTG2 APRO domain bridges PABPC1 RRM1 to CAF1 sufficiently to stimulate deadenylation and to control proliferation, and BTG2 was shown to restrain cardiomyocyte hypertrophy by lowering cytosolic RNA via deadenylation-complex binding.","evidence":"In vitro reconstitution with purified domains and interface mutagenesis plus proliferation assays; cardiomyocyte shRNA with single-cell RNA imaging and mass spectrometry of partners","pmids":["26912148","27346836"],"confidence":"High","gaps":["Identity of the proliferation-relevant decay substrates not defined","How PABPC1 bridging selects target mRNAs unknown"]},{"year":2017,"claim":"Identification of PRMT1-mediated CDK4 methylation as the mechanism by which the BTG2-PRMT1 module blocks CDK4-Cyclin D3 assembly provided a direct biochemical link from arginine methylation to cell-cycle arrest in pre-B cells.","evidence":"Co-IP, in vitro CDK4 methylation assay, CDK4-Cyclin D3 pulldown, conditional KO pre-B cells, and BCR-ABL1 transformation model in vivo","pmids":["28628091"],"confidence":"High","gaps":["Whether CDK4 methylation contributes to BTG2 function outside pre-B cells unknown","Relationship to deadenylation-driven cyclin loss not integrated"]},{"year":2020,"claim":"Genetic dissection in T cells established that BTG1/2-driven mRNA deadenylation maintains lymphocyte quiescence, and TRIM6 was identified as an E3 ligase ubiquitinating BTG2 at Lys5 to control its stability.","evidence":"Conditional double-KO mice with mRNA-seq, poly(A) tail and half-life measurements; IP/proteomics with TRIM6 C15A mutant, Lys5 mutagenesis, and CHX-chase","pmids":["32165587","31992359"],"confidence":"High","gaps":["Specific quiescence-determining transcripts not enumerated","Signals regulating TRIM6-BTG2 turnover unknown"]},{"year":2022,"claim":"BTG2 mRNA was shown to be controlled by m6A modification: VIRMA/KIAA1429-deposited m6A reduces BTG2 mRNA via YTHDF2-dependent decay, defining an upstream layer of BTG2 regulation.","evidence":"MeRIP-seq, RNA stability assay, KIAA1429 knockdown, and m6A dot blot","pmids":["35730068"],"confidence":"Medium","gaps":["Single-lab correlation; direct YTHDF2 binding to BTG2 m6A sites not fully mapped","Physiological contexts where this regulation operates limited"]},{"year":2023,"claim":"BTG2 was shown to bind Smad3 specifically and drive podocyte EMT in a TGF-β/Smad3-BTG2 feedback circuit, with podocyte-specific deletion protecting against glomerulosclerosis, extending BTG2's Smad-modulating role to disease.","evidence":"Podocyte-specific conditional KO, Co-IP discriminating Smad2 versus Smad3, SIS3 rescue, and ADR-induced FSGS model","pmids":["37749872"],"confidence":"Medium","gaps":["How BTG2 distinguishes Smad3 from Smad2 mechanistically unknown","Reconciliation with earlier BMP-Smad1/8 enhancement not addressed"]},{"year":null,"claim":"How BTG2 selects specific mRNAs for deadenylation versus broadly activating decay, and how its deadenylation and PRMT1-methylation activities are coordinated within a single antiproliferative program, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No defined transcript-selection rule for BTG2-driven decay","No unified model linking deadenylation, arginine methylation, and transcriptional co-regulation","Structural basis of context-specific Smad and nuclear-receptor partnering not solved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,12,13,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[11,18,21]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[24,7,30]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[12,26,29]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[31,12]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[11,18,21]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[12,24,26]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[3,8,9,14,25]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[1,16]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[11,18,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,30,23]}],"complexes":["CCR4-NOT deadenylase complex"],"partners":["PRMT1","CNOT7","PABPC1","SMAD1","SMAD3","PIN1","SKP2","NFE2L2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P78543","full_name":"Protein BTG2","aliases":["BTG family member 2","NGF-inducible anti-proliferative protein PC3"],"length_aa":158,"mass_kda":17.4,"function":"Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8. Involved in cell cycle regulation. Could be involved in the growth arrest and differentiation of the neuronal precursors (By similarity). Modulates transcription regulation mediated by ESR1. Involved in mitochondrial depolarization and neurite outgrowth","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P78543/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BTG2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BTG2","total_profiled":1310},"omim":[{"mim_id":"611052","title":"SET DOMAIN-CONTAINING PROTEIN 1A; SETD1A","url":"https://www.omim.org/entry/611052"},{"mim_id":"610016","title":"MICRO RNA 132; MIR132","url":"https://www.omim.org/entry/610016"},{"mim_id":"601597","title":"B-CELL ANTIPROLIFERATION FACTOR 2; BTG2","url":"https://www.omim.org/entry/601597"},{"mim_id":"109580","title":"B-CELL ANTIPROLIFERATION FACTOR 1; BTG1","url":"https://www.omim.org/entry/109580"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BTG2"},"hgnc":{"alias_symbol":["PC3","TIS21","MGC126063","MGC126064","APRO1"],"prev_symbol":[]},"alphafold":{"accession":"P78543","domains":[{"cath_id":"3.90.640.90","chopping":"8-123","consensus_level":"high","plddt":97.0706,"start":8,"end":123}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P78543","model_url":"https://alphafold.ebi.ac.uk/files/AF-P78543-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P78543-F1-predicted_aligned_error_v6.png","plddt_mean":85.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BTG2","jax_strain_url":"https://www.jax.org/strain/search?query=BTG2"},"sequence":{"accession":"P78543","fasta_url":"https://rest.uniprot.org/uniprotkb/P78543.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P78543/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P78543"}},"corpus_meta":[{"pmid":"8663146","id":"PMC_8663146","title":"The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8663146","citation_count":418,"is_preprint":false},{"pmid":"8944033","id":"PMC_8944033","title":"Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway.","date":"1996","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8944033","citation_count":381,"is_preprint":false},{"pmid":"11377414","id":"PMC_11377414","title":"In search of a function for the TIS21/PC3/BTG1/TOB family.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11377414","citation_count":216,"is_preprint":false},{"pmid":"11267995","id":"PMC_11267995","title":"The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair?","date":"2001","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11267995","citation_count":197,"is_preprint":false},{"pmid":"22266859","id":"PMC_22266859","title":"Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22266859","citation_count":178,"is_preprint":false},{"pmid":"10200315","id":"PMC_10200315","title":"Expression of the antiproliferative gene TIS21 at the onset of neurogenesis identifies single neuroepithelial cells that switch from proliferative to neuron-generating division.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10200315","citation_count":170,"is_preprint":false},{"pmid":"30350856","id":"PMC_30350856","title":"Tumor suppressors BTG1 and BTG2: Beyond growth control.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30350856","citation_count":167,"is_preprint":false},{"pmid":"19546886","id":"PMC_19546886","title":"Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma.","date":"2009","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19546886","citation_count":154,"is_preprint":false},{"pmid":"1713584","id":"PMC_1713584","title":"Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1713584","citation_count":150,"is_preprint":false},{"pmid":"32165587","id":"PMC_32165587","title":"mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32165587","citation_count":146,"is_preprint":false},{"pmid":"9712883","id":"PMC_9712883","title":"Interaction of BTG1 and p53-regulated BTG2 gene products with mCaf1, the murine homolog of a component of the yeast CCR4 transcriptional regulatory complex.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9712883","citation_count":126,"is_preprint":false},{"pmid":"25405282","id":"PMC_25405282","title":"BTG2: a rising star of tumor suppressors (review).","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25405282","citation_count":121,"is_preprint":false},{"pmid":"27409164","id":"PMC_27409164","title":"MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27409164","citation_count":118,"is_preprint":false},{"pmid":"29310680","id":"PMC_29310680","title":"MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.","date":"2018","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29310680","citation_count":113,"is_preprint":false},{"pmid":"11136725","id":"PMC_11136725","title":"Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signaling pathway.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11136725","citation_count":109,"is_preprint":false},{"pmid":"18337750","id":"PMC_18337750","title":"The BTG2 protein is a general activator of mRNA deadenylation.","date":"2008","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18337750","citation_count":108,"is_preprint":false},{"pmid":"31959200","id":"PMC_31959200","title":"Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression.","date":"2020","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31959200","citation_count":93,"is_preprint":false},{"pmid":"22614007","id":"PMC_22614007","title":"BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22614007","citation_count":91,"is_preprint":false},{"pmid":"16456675","id":"PMC_16456675","title":"TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule.","date":"2006","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16456675","citation_count":90,"is_preprint":false},{"pmid":"26132560","id":"PMC_26132560","title":"MiR-21 Protected Cardiomyocytes against Doxorubicin-Induced Apoptosis by Targeting BTG2.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26132560","citation_count":85,"is_preprint":false},{"pmid":"14996721","id":"PMC_14996721","title":"Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14996721","citation_count":82,"is_preprint":false},{"pmid":"20020054","id":"PMC_20020054","title":"Impaired terminal differentiation of hippocampal granule neurons and defective contextual memory in PC3/Tis21 knockout mice.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20020054","citation_count":73,"is_preprint":false},{"pmid":"18393292","id":"PMC_18393292","title":"TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop.","date":"2008","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/18393292","citation_count":70,"is_preprint":false},{"pmid":"26912148","id":"PMC_26912148","title":"BTG2 bridges PABPC1 RNA-binding domains and CAF1 deadenylase to control cell proliferation.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26912148","citation_count":69,"is_preprint":false},{"pmid":"9766435","id":"PMC_9766435","title":"Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin-dependent kinase 4 proteins due to overexpression of TIS21.","date":"1998","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/9766435","citation_count":68,"is_preprint":false},{"pmid":"15378000","id":"PMC_15378000","title":"Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15378000","citation_count":66,"is_preprint":false},{"pmid":"12360398","id":"PMC_12360398","title":"BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12360398","citation_count":65,"is_preprint":false},{"pmid":"15542835","id":"PMC_15542835","title":"B-cell translocation gene 2 (Btg2) regulates vertebral patterning by modulating bone morphogenetic protein/smad signaling.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15542835","citation_count":63,"is_preprint":false},{"pmid":"35730068","id":"PMC_35730068","title":"Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.","date":"2022","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35730068","citation_count":62,"is_preprint":false},{"pmid":"11814693","id":"PMC_11814693","title":"The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene.","date":"2002","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11814693","citation_count":60,"is_preprint":false},{"pmid":"29441724","id":"PMC_29441724","title":"PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.","date":"2018","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29441724","citation_count":59,"is_preprint":false},{"pmid":"12771185","id":"PMC_12771185","title":"BTG2 antiproliferative protein interacts with the human CCR4 complex existing in vivo in three cell-cycle-regulated forms.","date":"2003","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/12771185","citation_count":59,"is_preprint":false},{"pmid":"16782888","id":"PMC_16782888","title":"Btg2 enhances retinoic acid-induced differentiation by modulating histone H4 methylation and acetylation.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16782888","citation_count":58,"is_preprint":false},{"pmid":"34163177","id":"PMC_34163177","title":"m6A-Induced LncRNA MEG3 Suppresses the Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cell Through miR-544b/BTG2 Signaling.","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34163177","citation_count":53,"is_preprint":false},{"pmid":"15302583","id":"PMC_15302583","title":"TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15302583","citation_count":52,"is_preprint":false},{"pmid":"32129363","id":"PMC_32129363","title":"Genistein inhibits high fat diet-induced obesity through miR-222 by targeting BTG2 and adipor1.","date":"2020","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/32129363","citation_count":51,"is_preprint":false},{"pmid":"19728149","id":"PMC_19728149","title":"Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro.","date":"2009","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19728149","citation_count":50,"is_preprint":false},{"pmid":"15788397","id":"PMC_15788397","title":"Phosphorylation of serine 147 of tis21/BTG2/pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15788397","citation_count":48,"is_preprint":false},{"pmid":"23115191","id":"PMC_23115191","title":"Tis21 knock-out enhances the frequency of medulloblastoma in Patched1 heterozygous mice by inhibiting the Cxcl3-dependent migration of cerebellar neurons.","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23115191","citation_count":47,"is_preprint":false},{"pmid":"30621734","id":"PMC_30621734","title":"MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30621734","citation_count":46,"is_preprint":false},{"pmid":"28628091","id":"PMC_28628091","title":"The BTG2-PRMT1 module limits pre-B cell expansion by regulating the CDK4-Cyclin-D3 complex.","date":"2017","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28628091","citation_count":46,"is_preprint":false},{"pmid":"31603257","id":"PMC_31603257","title":"NUSAP1 knockdown inhibits cell growth and metastasis of non-small-cell lung cancer through regulating BTG2/PI3K/Akt signaling.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31603257","citation_count":44,"is_preprint":false},{"pmid":"18974182","id":"PMC_18974182","title":"Crystal structures of human BTG2 and mouse TIS21 involved in suppression of CAF1 deadenylase activity.","date":"2008","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/18974182","citation_count":42,"is_preprint":false},{"pmid":"35643814","id":"PMC_35643814","title":"Exosomal circRNA BTG2 derived from RBP-J overexpressed-macrophages inhibits glioma progression via miR-25-3p/PTEN.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35643814","citation_count":41,"is_preprint":false},{"pmid":"8263025","id":"PMC_8263025","title":"Synthesis, degradation, and subcellular localization of proteins encoded by the primary response genes TIS7/PC4 and TIS21/PC3.","date":"1994","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8263025","citation_count":40,"is_preprint":false},{"pmid":"15381462","id":"PMC_15381462","title":"BTG2, its family and its tutor.","date":"2004","source":"Bulletin du cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15381462","citation_count":39,"is_preprint":false},{"pmid":"23876794","id":"PMC_23876794","title":"Regulation of Btg2(/TIS21/PC3) expression via reactive oxygen species-protein kinase C-ΝFκΒ pathway under stress conditions.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23876794","citation_count":39,"is_preprint":false},{"pmid":"24726360","id":"PMC_24726360","title":"3' UTR-dependent, miR-92-mediated restriction of Tis21 expression maintains asymmetric neural stem cell division to ensure proper neocortex size.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24726360","citation_count":39,"is_preprint":false},{"pmid":"29239139","id":"PMC_29239139","title":"BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells.","date":"2017","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29239139","citation_count":39,"is_preprint":false},{"pmid":"32746503","id":"PMC_32746503","title":"SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32746503","citation_count":39,"is_preprint":false},{"pmid":"20569234","id":"PMC_20569234","title":"BTG2 antagonizes Pin1 in response to mitogens and telomere disruption during replicative senescence.","date":"2010","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/20569234","citation_count":39,"is_preprint":false},{"pmid":"7768965","id":"PMC_7768965","title":"Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines.","date":"1995","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/7768965","citation_count":38,"is_preprint":false},{"pmid":"33270982","id":"PMC_33270982","title":"miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33270982","citation_count":37,"is_preprint":false},{"pmid":"35880434","id":"PMC_35880434","title":"Emerging role of anti-proliferative protein BTG1 and BTG2.","date":"2022","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/35880434","citation_count":36,"is_preprint":false},{"pmid":"31992359","id":"PMC_31992359","title":"TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1.","date":"2020","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31992359","citation_count":35,"is_preprint":false},{"pmid":"25798836","id":"PMC_25798836","title":"Inhibition of breast cancer invasion by TIS21/BTG2/Pc3-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25798836","citation_count":34,"is_preprint":false},{"pmid":"19482889","id":"PMC_19482889","title":"Tis21 expression marks not only populations of neurogenic precursor cells but also new postmitotic neurons in adult hippocampal neurogenesis.","date":"2009","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/19482889","citation_count":34,"is_preprint":false},{"pmid":"25576360","id":"PMC_25576360","title":"miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25576360","citation_count":34,"is_preprint":false},{"pmid":"22392501","id":"PMC_22392501","title":"Effects of BTG2 on proliferation inhibition and anti-invasion in human lung cancer cells.","date":"2012","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22392501","citation_count":34,"is_preprint":false},{"pmid":"37749872","id":"PMC_37749872","title":"Btg2 Promotes Focal Segmental Glomerulosclerosis via Smad3-Dependent Podocyte-Mesenchymal Transition.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37749872","citation_count":33,"is_preprint":false},{"pmid":"34082648","id":"PMC_34082648","title":"MicroRNA miR-92a-3p regulates breast cancer cell proliferation and metastasis via regulating B-cell translocation gene 2 (BTG2).","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34082648","citation_count":33,"is_preprint":false},{"pmid":"26151427","id":"PMC_26151427","title":"MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26151427","citation_count":32,"is_preprint":false},{"pmid":"26722427","id":"PMC_26722427","title":"BTG2 inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/AKT pathway.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722427","citation_count":30,"is_preprint":false},{"pmid":"23420441","id":"PMC_23420441","title":"BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23420441","citation_count":30,"is_preprint":false},{"pmid":"23089312","id":"PMC_23089312","title":"TIS21(/BTG2/PC3) accelerates the repair of DNA double strand breaks by enhancing Mre11 methylation and blocking damage signal transfer to the Chk2(T68)-p53(S20) pathway.","date":"2012","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/23089312","citation_count":28,"is_preprint":false},{"pmid":"18194438","id":"PMC_18194438","title":"Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis21.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18194438","citation_count":28,"is_preprint":false},{"pmid":"29352138","id":"PMC_29352138","title":"miR-663 sustains NSCLC by inhibiting mitochondrial outer membrane permeabilization (MOMP) through PUMA/BBC3 and BTG2.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29352138","citation_count":28,"is_preprint":false},{"pmid":"19263516","id":"PMC_19263516","title":"TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest.","date":"2009","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/19263516","citation_count":27,"is_preprint":false},{"pmid":"22493435","id":"PMC_22493435","title":"B-cell translocation gene 2 (BTG2) stimulates cellular antioxidant defenses through the antioxidant transcription factor NFE2L2 in human mammary epithelial cells.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22493435","citation_count":27,"is_preprint":false},{"pmid":"25284287","id":"PMC_25284287","title":"Inhibition of bladder cancer invasion by Sp1-mediated BTG2 expression via inhibition of DNA methyltransferase 1.","date":"2014","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25284287","citation_count":26,"is_preprint":false},{"pmid":"33725320","id":"PMC_33725320","title":"Elevation of miR-146a Inhibits BTG2/BAX Expression to Ameliorate Postoperative Cognitive Dysfunction Following Probiotics (VSL#3) Treatment.","date":"2021","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/33725320","citation_count":26,"is_preprint":false},{"pmid":"11237868","id":"PMC_11237868","title":"Mitogen-stimulated TIS21 protein interacts with a protein-kinase-Calpha-binding protein rPICK1.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11237868","citation_count":25,"is_preprint":false},{"pmid":"30115961","id":"PMC_30115961","title":"Estradiol Prevents High Glucose-Induced β-cell Apoptosis by Decreased BTG2 Expression.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30115961","citation_count":25,"is_preprint":false},{"pmid":"21327578","id":"PMC_21327578","title":"Aberrant expression of the p53-inducible antiproliferative gene BTG2 in hepatocellular carcinoma is associated with overexpression of the cell cycle-related proteins.","date":"2011","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/21327578","citation_count":25,"is_preprint":false},{"pmid":"25967096","id":"PMC_25967096","title":"Control of the Normal and Pathological Development of Neural Stem and Progenitor Cells by the PC3/Tis21/Btg2 and Btg1 Genes.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25967096","citation_count":24,"is_preprint":false},{"pmid":"33812385","id":"PMC_33812385","title":"Deletion of B-cell translocation gene 2 (BTG2) alters the responses of glial cells in white matter to chronic cerebral hypoperfusion.","date":"2021","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/33812385","citation_count":24,"is_preprint":false},{"pmid":"17890019","id":"PMC_17890019","title":"Molecular characterization of the BTG2 and BTG3 genes in fetal muscle development of pigs.","date":"2007","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/17890019","citation_count":24,"is_preprint":false},{"pmid":"18773938","id":"PMC_18773938","title":"PRMT1 and Btg2 regulates neurite outgrowth of Neuro2a cells.","date":"2008","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/18773938","citation_count":24,"is_preprint":false},{"pmid":"18556508","id":"PMC_18556508","title":"TIS21/(BTG2) negatively regulates estradiol-stimulated expansion of hematopoietic stem cells by derepressing Akt phosphorylation and inhibiting mTOR signal transduction.","date":"2008","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/18556508","citation_count":23,"is_preprint":false},{"pmid":"22341854","id":"PMC_22341854","title":"TIS21/BTG2/PC3 enhances downregulation of c-Myc during differentiation of HL-60 cells by activating Erk1/2 and inhibiting Akt in response to all-trans-retinoic acid.","date":"2012","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/22341854","citation_count":23,"is_preprint":false},{"pmid":"16163674","id":"PMC_16163674","title":"The BTG/TOB family protein TIS21 regulates stage-specific proliferation of developing thymocytes.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16163674","citation_count":23,"is_preprint":false},{"pmid":"29098552","id":"PMC_29098552","title":"BTG2 Is Down-Regulated and Inhibits Cancer Stem Cell-Like Features of Side Population Cells in Hepatocellular Carcinoma.","date":"2017","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29098552","citation_count":23,"is_preprint":false},{"pmid":"27346836","id":"PMC_27346836","title":"Btg2 is a Negative Regulator of Cardiomyocyte Hypertrophy through a Decrease in Cytosolic RNA.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27346836","citation_count":23,"is_preprint":false},{"pmid":"34337864","id":"PMC_34337864","title":"Exosomal microRNA-15a from ACHN cells aggravates clear cell renal cell carcinoma via the BTG2/PI3K/AKT axis.","date":"2021","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34337864","citation_count":22,"is_preprint":false},{"pmid":"24744701","id":"PMC_24744701","title":"Tis21 is required for adult neurogenesis in the subventricular zone and for olfactory behavior regulating cyclins, BMP4, Hes1/5 and Ids.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24744701","citation_count":22,"is_preprint":false},{"pmid":"23857284","id":"PMC_23857284","title":"Expression and significance of miRNA-21 and BTG2 in lung cancer.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23857284","citation_count":21,"is_preprint":false},{"pmid":"36789695","id":"PMC_36789695","title":"DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling.","date":"2022","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/36789695","citation_count":21,"is_preprint":false},{"pmid":"19117054","id":"PMC_19117054","title":"Estradiol downregulation of the tumor suppressor gene BTG2 requires estrogen receptor-alpha and the REA corepressor.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19117054","citation_count":21,"is_preprint":false},{"pmid":"33025678","id":"PMC_33025678","title":"LINC01089 inhibits the progression of cervical cancer via inhibiting miR-27a-3p and increasing BTG2.","date":"2020","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33025678","citation_count":21,"is_preprint":false},{"pmid":"24780075","id":"PMC_24780075","title":"Association of BTG2, CYR61, ZFP36, and SCD gene polymorphisms with Graves' disease and ophthalmopathy.","date":"2014","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/24780075","citation_count":20,"is_preprint":false},{"pmid":"9712737","id":"PMC_9712737","title":"Overexpression of the PC3/TIS21/BTG2 mRNA is part of the stress response induced by acute pancreatitis in rats.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9712737","citation_count":20,"is_preprint":false},{"pmid":"37131441","id":"PMC_37131441","title":"miR-21-5p prevents doxorubicin-induced cardiomyopathy by downregulating BTG2.","date":"2023","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/37131441","citation_count":19,"is_preprint":false},{"pmid":"40446574","id":"PMC_40446574","title":"Predicting the molecular mechanism of ginger targeting PRMT1/BTG2 axis to inhibit gastric cancer based on WGCNA and machine algorithms.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40446574","citation_count":18,"is_preprint":false},{"pmid":"19615363","id":"PMC_19615363","title":"Skp2 enhances polyubiquitination and degradation of TIS21/BTG2/PC3, tumor suppressor protein, at the downstream of FoxM1.","date":"2009","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19615363","citation_count":18,"is_preprint":false},{"pmid":"23907596","id":"PMC_23907596","title":"TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells.","date":"2013","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23907596","citation_count":18,"is_preprint":false},{"pmid":"33598424","id":"PMC_33598424","title":"Circular RNA circ_0014717 Suppresses Hepatocellular Carcinoma Tumorigenesis Through Regulating miR-668-3p/BTG2 Axis.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33598424","citation_count":18,"is_preprint":false},{"pmid":"30912184","id":"PMC_30912184","title":"The effect of decitabine on the expression and methylation of the PPP1CA, BTG2, and PTEN in association with changes in miR-125b, miR-17, and miR-181b in NALM6 cell line.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30912184","citation_count":18,"is_preprint":false},{"pmid":"31885582","id":"PMC_31885582","title":"lncRNA SNHG5 Modulates Endometrial Cancer Progression via the miR-25-3p/BTG2 Axis.","date":"2019","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31885582","citation_count":18,"is_preprint":false},{"pmid":"28740463","id":"PMC_28740463","title":"Terminal Differentiation of Adult Hippocampal Progenitor Cells Is a Step Functionally Dissociable from Proliferation and Is Controlled by Tis21, Id3 and NeuroD2.","date":"2017","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28740463","citation_count":17,"is_preprint":false},{"pmid":"24308156","id":"PMC_24308156","title":"BTG2 overexpression increases the radiosensitivity of breast cancer cells in vitro and in vivo.","date":"2013","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/24308156","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51800,"output_tokens":9171,"usd":0.146482,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19249,"output_tokens":6134,"usd":0.124798,"stage2_stop_reason":"end_turn"},"total_usd":0.27128,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"BTG2/TIS21 interacts physically with PRMT1 (protein-arginine N-methyltransferase 1), and GST-TIS21 fusion protein modulates endogenous PRMT1 methyltransferase activity on protein substrates, suggesting BTG2 acts as a regulatory subunit of PRMT1.\",\n      \"method\": \"Yeast two-hybrid screening, GST pulldown, in vitro methyltransferase activity assay with cell extracts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — yeast two-hybrid plus GST pulldown plus direct enzymatic activity assay, replicated across BTG1 and TIS21; foundational biochemical study\",\n      \"pmids\": [\"8663146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"BTG2 expression is induced by p53 in response to DNA damage and its overexpression inhibits cell proliferation, placing BTG2 as a p53-dependent component of the DNA damage cellular response pathway.\",\n      \"method\": \"p53-inducible gene identification, transfection overexpression with proliferation/cell-cycle readouts\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — p53-dependent transcriptional induction demonstrated experimentally; antiproliferative function confirmed by overexpression; widely replicated by subsequent studies\",\n      \"pmids\": [\"8944033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BTG1 and BTG2 physically interact with mCaf1 (mouse CCR4-associated factor 1) in vitro and in vivo, and the conserved Box B domain of BTG proteins is essential for the BTG–mCaf1 interaction, suggesting BTG2 participates in transcriptional regulation via the CCR4 complex.\",\n      \"method\": \"Yeast two-hybrid screening, GST pulldown (in vitro binding assay), co-immunoprecipitation in HeLa cells, transient transfection, Box B deletion mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal in vitro and in vivo binding confirmed; domain mapped by deletion mutagenesis; orthogonal methods in single rigorous study\",\n      \"pmids\": [\"9712883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Overexpression of TIS21 in 293 cells reduces synthesis of cyclin E and CDK4 proteins and decreases cyclin E-associated CDK kinase activity, causing G1 accumulation, identifying cyclin E and CDK4 downregulation as a mechanism of TIS21-induced G1 arrest.\",\n      \"method\": \"Stable transfection, FACS cell-cycle analysis (double thymidine block), western blot for cyclin E and CDK4, cyclin E-associated kinase activity assay\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean stable-expression system with biochemical readouts; single lab, two orthogonal methods\",\n      \"pmids\": [\"9766435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BTG1 and BTG2 interact with both hCAF1 and hPOP2 (human paralogs of the yeast CCR4-associated factors) in vitro and in vivo, and LXXLL nuclear receptor box motifs in BTG1/BTG2 are involved in regulating estrogen receptor alpha (ERα)-mediated transcription, demonstrating that BTG2 can modulate ERα function through the CCR4-like complex.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, interaction domain mapping, transient transfection reporter assays for ERα transcriptional activity\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, domain mapping, functional reporter assays; multiple orthogonal methods in one study\",\n      \"pmids\": [\"11136725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TIS21/BTG2 protein interacts physically with rPICK1 (a PKCα-binding protein) via PICK1's PDZ domain, and this interaction modulates PKC-mediated phosphorylation of TIS21, suggesting a role for BTG2 in PKC signal transduction.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown with in vitro translated TIS21, co-immunoprecipitation from NIH 3T3 cells, PDZ domain deletion mutagenesis, in vitro PKC phosphorylation assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding confirmed in vitro and in vivo; domain mapped; single lab\",\n      \"pmids\": [\"11237868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BTG2 interacts in vivo with hCCR4 protein via hCAF1 and hPOP2 within mammalian CCR4-NOT complexes of ~650 kDa, ~1 MDa, and ~1.9 MDa; hCAF1 cellular localization changes as cells progress from quiescence to S phase, suggesting distinct CCR4 complexes mediate different BTG2 functions at different cell-cycle stages.\",\n      \"method\": \"Immunoprecipitation, gel filtration chromatography, cell-cycle fractionation, transient transfection reporter assays for ERα activity\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gel filtration plus Co-IP establish complex composition and size; single lab\",\n      \"pmids\": [\"12771185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BTG2 physically interacts with BMP-activated Smad proteins (Smad1/Smad8) and enhances BMP transcriptional signaling, as demonstrated biochemically and by the vertebral patterning phenotype in Btg2-null mice which phenocopies reduced BMP signaling.\",\n      \"method\": \"Btg2-knockout mouse generation, vertebral phenotype analysis, co-immunoprecipitation/pulldown of Btg2 with Smad1/Smad8, transcriptional reporter assays for BMP signaling\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic knockout phenotype plus biochemical interaction evidence; functional epistasis with BMP pathway; multiple orthogonal approaches in single study\",\n      \"pmids\": [\"15542835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BTG2 expression is induced by NF-κB activation in breast cancer cells, and BTG2 inhibits breast cancer cell growth by arresting cells in G1 through suppression of cyclin D1 expression; this effect is reversed by cyclin D1 re-expression.\",\n      \"method\": \"NF-κB stimulation assays, BTG2 ectopic expression in breast cancer cells, growth arrest assays, rescue experiment with cyclin D1 overexpression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue experiment with cyclin D1 directly links BTG2 to cyclin D1-dependent G1 arrest; single lab\",\n      \"pmids\": [\"15378000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TIS21/BTG2 is expressed through a PKC-delta signaling pathway and inhibits cyclin B1-Cdc2 binding and kinase activity in vivo (G2/M inhibition), independent of p53; TIS21 also stabilizes cyclin A and cyclin B1 by preventing their degradation.\",\n      \"method\": \"PKC inhibitor pharmacology, dnPKC-delta transfection, nocodazole synchronization, co-immunoprecipitation of cyclin B1-Cdc2, in vivo kinase assay, FACS analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase activity assay plus Co-IP plus pharmacological epistasis; single lab, multiple methods\",\n      \"pmids\": [\"15302583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"p-Erk1/2 phosphorylates TIS21 at Ser147; this phosphorylation promotes binding of TIS21 to Pin1 (prolyl isomerase), which causes Pin1 relocalization to the cytoplasm and subsequent mitochondrial depolarization and cell death. The P148A mutation abolishes Pin1 binding.\",\n      \"method\": \"In vitro kinase assay with p-Erk1/2 and p-p38, site-directed mutagenesis (P148A), co-immunoprecipitation, shRNAi knockdown of TIS21, confocal microscopy of Pin1 localization, flow cytometry (JC-1 mitochondrial membrane potential)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, mutagenesis, and functional cellular readouts (mitochondrial depolarization, cell death) all in one study; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15788397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BTG2 enhances PRMT1 participation in the RARα transcriptional complex on the RARβ promoter, increases histone H4 arginine methylation at this gene in the absence of retinoic acid, and upon retinoic acid treatment BTG2 and PRMT1 dissociate from RARα, enabling histone H4 demethylation and acetylation that prime differentiation.\",\n      \"method\": \"Co-immunoprecipitation of RARα complex, chromatin immunoprecipitation (ChIP) for H4 arginine methylation and acetylation at RARβ promoter, overexpression in myeloid leukemia cells and CD34+ progenitors, differentiation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP plus Co-IP demonstrate mechanism at specific promoter; functional differentiation readout; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16782888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BTG2 is a general activator of mRNA deadenylation: it stimulates poly(A) tail shortening of all transcripts tested through its interaction with the CAF1/CCR4 deadenylase complex; CAF1 nuclease activity is required for efficient deadenylation, and both CAF1 and CCR4 deadenylase activities are required for BTG2-induced poly(A) degradation.\",\n      \"method\": \"In vitro deadenylation assays with reporter mRNAs, CAF1 nuclease-dead mutants, BTG2 overexpression in mammalian cells, mRNA half-life measurements\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of deadenylation plus mutagenesis of catalytic residues plus cellular mRNA decay assays; multiple orthogonal methods\",\n      \"pmids\": [\"18337750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structures of human BTG2 and mouse TIS21 were solved to 2.3 Å and 2.2 Å resolution, respectively; the structures reveal a putative CAF1 binding site; structure-guided mutagenesis of BTG2 at this site reduces CAF1 deadenylase activity, demonstrating that BTG2 suppresses CAF1 deadenylase activity through direct structural interaction.\",\n      \"method\": \"X-ray crystallography, in vitro CAF1 deadenylase activity assay with wild-type and interface mutant BTG2\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus structure-guided mutagenesis plus direct enzymatic assay; multiple orthogonal methods in single study\",\n      \"pmids\": [\"18974182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TIS21 inhibits FoxM1 phosphorylation (required for FoxM1 activation) by reducing cyclin B1-CDK1 kinase activity, thereby disrupting the FoxM1-cyclin B1 regulatory loop; this was confirmed by in vitro kinase assay, FoxM1 mutant analyses, and in vivo reciprocal expression studies.\",\n      \"method\": \"In vitro kinase assay, FoxM1 phosphorylation mutant analysis, TIS21 forced expression in Huh7 cells, TIS21-null mouse embryonic fibroblasts, DEN-induced hepatocarcinoma model\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro kinase assay with mutagenesis, complemented by in vivo genetic model; single lab but rigorous multi-method approach\",\n      \"pmids\": [\"18393292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PRMT1 plays a pivotal role in neurite outgrowth of Neuro2a cells, and BTG2 (a PRMT1 binding partner) depletion downregulates nuclear arginine methylation and inhibits neurite outgrowth, indicating the BTG2-PRMT1 interaction is functionally required for arginine methylation-dependent neuronal differentiation.\",\n      \"method\": \"shRNA knockdown of PRMT1 and Btg2 in Neuro2a cells, immunofluorescence for neurite morphology, western blot for methylarginine marks\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular phenotype; single lab, single method per protein\",\n      \"pmids\": [\"18773938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TIS21 promotes repair of DNA double-strand breaks by increasing PRMT1-dependent arginine methylation of Mre11, activating Mre11 nuclease activity; TIS21 also blocks the ATM→Chk2(T68)→p53(S20) damage signal cascade while not affecting p53(S15) phosphorylation, thereby reducing apoptosis after etoposide treatment.\",\n      \"method\": \"Adenoviral TIS21 transduction of Huh7 cells, γH2AX foci clearance assay, Comet assay, immunoprecipitation and radiolabeling for Mre11 methylation, PRMT1 in vitro activity assay, western blot for Chk2 and p53 phosphorylation, TIS21-null MEFs\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct enzymatic assay (PRMT1, Mre11 methylation), γH2AX foci, Comet assay, phospho-signaling, and genetic KO MEFs; multiple orthogonal methods\",\n      \"pmids\": [\"23089312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BTG2 depletion in human fibroblasts extends cellular lifespan, and ectopic BTG2 induces senescence independently of p53; BTG2 is stabilized by telomere dysfunction and serum-dependently binds and relocalizes Pin1 (prolyl isomerase), and Pin1 inhibition leads to senescence while ectopic Pin1 rescues BTG2-induced senescence.\",\n      \"method\": \"siRNA depletion, ectopic overexpression, co-immunoprecipitation of BTG2-Pin1, cellular lifespan/senescence assays, Pin1 overexpression rescue experiment in late-passage fibroblasts\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (rescue by Pin1 OE) plus Co-IP; single lab, two orthogonal approaches\",\n      \"pmids\": [\"20569234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PC3/Tis21 deletion causes increased proliferation of adult dentate gyrus progenitor cells and arrest of their terminal differentiation, with accumulation of undifferentiated postmitotic neurons and reduced terminally differentiated neurons; PC3/Tis21 associates with the Id3 promoter and negatively regulates Id3 expression, placing Tis21 upstream of Id3 in the differentiation cascade.\",\n      \"method\": \"PC3/Tis21-null mouse analysis, BrdU/NeuN neurogenesis markers, ChIP for Tis21 at Id3 promoter, immunofluorescence, Morris water maze behavioral assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined cellular phenotype, ChIP for direct promoter binding, behavioral functional readout; multiple orthogonal methods\",\n      \"pmids\": [\"20020054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SKP2 (SCF ubiquitin ligase subunit) binds to the C-terminus of TIS21 via its leucine-rich repeat (LRR) domain and promotes polyubiquitination and proteasomal degradation of TIS21; FoxM1 regulates Skp2 expression and thereby controls TIS21 protein stability.\",\n      \"method\": \"Co-immunoprecipitation, deletion mutagenesis of Skp2 (ΔLRR) and TIS21 (ΔC), ubiquitination assays, cycloheximide chase (protein half-life), siRNA knockdown of Skp2, FoxM1 co-expression\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus deletion mutagenesis plus ubiquitination assay; single lab\",\n      \"pmids\": [\"19615363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TIS21/BTG2 inhibits invadopodia formation in MDA-MB-231 breast cancer cells by downregulating intracellular reactive oxygen species (ROS) levels, with consequent F-actin remodeling; this was confirmed in TIS21-null MEFs which show enhanced invadopodia.\",\n      \"method\": \"Adenoviral TIS21 transduction, invadopodia/gelatin degradation assay, Matrigel invasion assay, FACS-based ROS measurement (DCFH-DA), TIS21-null MEF controls\",\n      \"journal\": \"Journal of cancer research and clinical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss- and gain-of-function with defined cellular phenotype; genetic KO confirmation; single lab\",\n      \"pmids\": [\"23907596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BTG2 stimulates antioxidant gene expression (catalase, SOD1, SOD2) through direct interaction with the transcription factor NFE2L2 (Nrf2); BTG2 is detectable at the antioxidant response element (ARE) of NFE2L2-responsive genes by ChIP; the conserved Box B domain is required for BTG2-NFE2L2 interaction, protection against oxidative stress, and antioxidant gene upregulation.\",\n      \"method\": \"Co-immunoprecipitation for BTG2-NFE2L2 interaction, ChIP at ARE elements, cell viability assays under H2O2 stress, siRNA knockdown of NFE2L2, Box B deletion mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct Co-IP, ChIP at endogenous promoters, domain mutagenesis, functional rescue; multiple orthogonal methods\",\n      \"pmids\": [\"22493435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BTG2 loss shifts normal prostate basal cells toward luminal marker expression and induces EMT traits; miR-21 overexpression suppresses BTG2 levels and promotes luminal/EMT phenotype; derepression of BTG2 via a decoy 3'-UTR construct reduces luminal and EMT markers in prostate tumor cells and abrogates orthotopic tumor growth.\",\n      \"method\": \"BTG2 knockdown/lentiviral 3'-UTR decoy in prostate cell lines, immunofluorescence for luminal/EMT markers, miR-21 overexpression, orthotopic murine model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — decoy 3'-UTR derepression experiment plus in vivo orthotopic model; mechanistic link between BTG2 and EMT; single lab\",\n      \"pmids\": [\"22614007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIS21/BTG2 inhibits breast cancer cell invasion through a TIS21-Akt1-Sp1-Nox4 pathway: TIS21 activates Akt1, which reduces Sp1-mediated Nox4 transcription, decreasing Nox4-derived ROS and thereby inhibiting mDia (diaphanous-related formin) expression and F-actin remodeling required for invasion.\",\n      \"method\": \"RNA interference knockdown of Akt1, adenoviral TIS21 transduction, Nox4 promoter reporter assays, ROS measurement, Matrigel invasion assay, western blot for mDia/actin regulators\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via Akt1 knockdown plus promoter reporter assays plus ROS measurement; single lab, multiple methods\",\n      \"pmids\": [\"25798836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTG2 APRO domain directly interacts with the first RRM domain of PABPC1 (cytoplasmic poly(A)-binding protein); PABPC1 RRM1 and BTG2 APRO domains together are sufficient to stimulate CAF1 deadenylase activity in vitro without other CCR4-NOT subunits; this BTG2-PABPC1 interaction is required for BTG2 to control cell proliferation.\",\n      \"method\": \"In vitro reconstitution of deadenylation assay with purified domains, pulldown/binding assays for APRO-RRM1 interaction, mutagenesis of interaction interface, cell proliferation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with minimal components, mutagenesis, and functional cellular readout; single lab but multiple orthogonal methods in rigorous study\",\n      \"pmids\": [\"26912148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BTG2 and PRMT1 form a module in pre-B cells that induces cell-cycle arrest by enabling PRMT1 to methylate CDK4, thereby preventing CDK4-Cyclin D3 complex formation and blocking cell cycle progression; BTG2-PRMT1 also blocks proliferation of BCR-ABL1-transformed pre-B cells in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation, in vitro methylation assay for CDK4 by PRMT1, CDK4-Cyclin D3 complex pulldown, BTG2/PRMT1 conditional knockout pre-B cells, BCR-ABL1 transformation model in vivo\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct in vitro methylation assay of CDK4 plus Co-IP of CDK4-CyclinD3 complex plus genetic KO, in vivo model; multiple orthogonal methods\",\n      \"pmids\": [\"28628091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BTG1 and BTG2 (BTG1/2) promote mRNA deadenylation and degradation to maintain T cell quiescence; BTG1/2-deficient T cells show increased global mRNA abundance with longer poly(A) tails and greater mRNA half-lives, reducing the activation threshold; this establishes mRNA deadenylation as the mechanism underlying BTG2-dependent T cell quiescence.\",\n      \"method\": \"Conditional BTG1/2 double-knockout mice, global mRNA-seq, poly(A) tail length measurement, mRNA half-life assays, T cell proliferation and spontaneous activation assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-KO with genome-wide mRNA abundance and poly(A) tail length measurements; mechanistic link between BTG2, deadenylation, and quiescence replicated in multiple assays\",\n      \"pmids\": [\"32165587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRIM6 E3 ubiquitin ligase interacts with TIS21/BTG2, promotes its polyubiquitination at Lys5, and decreases TIS21 protein stability; a TRIM6 catalytic mutant (C15A) fails to ubiquitinate TIS21; TIS21 overexpression reverses TRIM6-driven cell proliferation and suppresses FoxM1/cyclin B1 signaling.\",\n      \"method\": \"Immunoprecipitation, proteomics, ubiquitination assay with TRIM6 WT and C15A mutant, cycloheximide chase, site-directed mutagenesis of TIS21 (Lys5), TIS21 overexpression rescue assays\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay with E3 catalytic mutant plus Lys5 mutagenesis; single lab, two orthogonal methods\",\n      \"pmids\": [\"31992359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"KIAA1429 (VIRMA, an m6A RNA methyltransferase) mediates m6A modification of BTG2 mRNA; knockdown of KIAA1429 decreases BTG2 mRNA m6A levels, leading to increased YTHDF2 (m6A reader)-dependent BTG2 mRNA stability and elevated BTG2 expression, placing BTG2 regulation downstream of m6A mRNA modification.\",\n      \"method\": \"MeRIP-seq (methylated RNA immunoprecipitation sequencing), RNA stability assay, KIAA1429 knockdown, transcriptome-seq, m6A dot blot\",\n      \"journal\": \"Cancer communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeRIP-seq plus RNA stability assay mechanistically link m6A on BTG2 mRNA to YTHDF2-dependent stability; single lab\",\n      \"pmids\": [\"35730068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Btg2 negatively regulates cardiomyocyte hypertrophy by reducing cytosolic (but not nuclear) RNA levels; Btg2 binds components of mRNA deadenylation complexes as shown by mass spectrometry; Btg2 knockdown enhances cytosolic RNA accumulation under adrenergic stimulation.\",\n      \"method\": \"Btg2 shRNA knockdown in cardiomyocytes, Myc-mediated hypermetabolic model, single-cell RNA imaging with nascent RNA labeling, ChIP-seq, mass spectrometry of Btg2-associated proteins, cardiomyocyte surface area measurement\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry identifies deadenylation complex partners; shRNA KD with RNA quantification; single lab, multiple methods\",\n      \"pmids\": [\"27346836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BTG2 promotes podocyte-to-mesenchymal transition (EMT) and FSGS by binding specifically to Smad3 (not Smad2) and enhancing Smad3 signaling; podocyte-specific deletion of Btg2 protects against proteinuria and glomerulosclerosis; a TGF-β/Smad3–Btg2 positive feedback circuit was identified.\",\n      \"method\": \"Podocyte-specific Btg2 conditional knockout mice, co-immunoprecipitation of Btg2 with Smad2 vs Smad3, Smad3 inhibitor (SIS3) rescue, Btg2 overexpression in cultured MPC5 podocytes, ADR-induced FSGS model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined phenotype plus Co-IP distinguishing Smad2 vs Smad3 specificity; single lab, two orthogonal methods\",\n      \"pmids\": [\"37749872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The TIS21/PC3 protein is a non-nuclear, soluble intracellular protein (not secreted and not membrane-associated), as established by immunohistochemistry and subcellular fractionation experiments; the protein is synthesized rapidly after stimulation and is degraded much more rapidly than the related TIS7/PC4 protein.\",\n      \"method\": \"Pulse-chase metabolic labeling, subcellular fractionation, immunohistochemistry with anti-TIS21 antiserum\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation plus immunohistochemistry; single lab; negative result (no secretion detected) rigorously established\",\n      \"pmids\": [\"8263025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Tis21 deletion in Patched1 heterozygous mice increases medulloblastoma frequency; genome-wide analysis identified Cxcl3 as a transcriptional target of Tis21; Tis21-null cerebellar granule neuron precursors show downregulated Cxcl3 and defective migration; addition of exogenous Cxcl3 rescues migration defect and reduces hyperplastic lesion area, placing Tis21 upstream of Cxcl3-dependent GCP migration.\",\n      \"method\": \"Double-KO mouse cross (Tis21-/-; Ptch1+/-), genome-wide gene expression analysis, cerebellar slice migration assay, Cxcl3 protein addition rescue experiment\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo plus rescue experiment with defined molecular target; genome-wide identification of Cxcl3 as Tis21 target; multiple orthogonal approaches\",\n      \"pmids\": [\"23115191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In TIS21-null mice, p-Erk1/2 preferentially binds Akt (preventing Akt activation), and mTOR is constitutively active; reconstitution of TIS21 inhibits p-Erk1/2-Akt interaction; TIS21 thereby negatively regulates estradiol-stimulated hematopoietic stem cell expansion through this Akt/mTOR axis.\",\n      \"method\": \"TIS21 knockout mice, co-immunoprecipitation of p-Erk1/2 with Akt, TIS21 reconstitution in MEFs, Erk1 siRNA knockdown, rapamycin treatment, LSK flow cytometry of bone marrow\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus reconstitution rescue plus genetic KO; single lab, multiple methods\",\n      \"pmids\": [\"18556508\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BTG2 (TIS21/PC3) is a multifunctional antiproliferative protein that acts primarily as a transcriptional co-regulator and mRNA decay activator: it binds the CAF1/CCR4-NOT deadenylase complex (via its APRO domain) and simultaneously bridges PABPC1's RRM1 domain to stimulate poly(A) tail shortening and mRNA degradation; it interacts with and modulates PRMT1 arginine methyltransferase activity, directing histone H4 arginine methylation at specific promoters (e.g., RARβ) and CDK4 methylation to block cell cycle progression; it is transcriptionally induced by p53 after DNA damage and by NF-κB under stress; it promotes DNA double-strand break repair by enhancing PRMT1-mediated Mre11 methylation while blocking ATM→Chk2→p53(S20) signaling; its protein stability is controlled by Skp2-mediated polyubiquitination (at Lys5) regulated by FoxM1, and by Erk1/2-dependent phosphorylation at Ser147 that recruits Pin1 to induce mitochondrial depolarization; it enhances BMP/Smad signaling and suppresses cyclin D1, cyclin E, and CDK4 levels to enforce G1 arrest, inhibits cyclin B1-CDK1 activity to cause G2/M arrest, and activates Akt1 to suppress Nox4-ROS-mDia-dependent cancer cell invasion.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BTG2 (TIS21/PC3) is an antiproliferative protein that enforces cell-cycle exit and quiescence through two convergent activities: activation of mRNA deadenylation and regulation of arginine methylation, both deployed downstream of stress and damage signals [#12, #16, #26]. As a deadenylation activator, BTG2 binds the CAF1/CCR4-NOT complex via its conserved Box B/APRO domain and stimulates poly(A) tail shortening of transcripts, a function dissected biochemically and structurally: the BTG2 APRO domain bridges the first RRM domain of PABPC1 to CAF1, and these minimal components are sufficient to stimulate deadenylation and are required for BTG2 to control proliferation [#2, #12, #13, #24]. Genetic loss of BTG1/2 in T cells globally lengthens poly(A) tails and stabilizes mRNAs, lowering the activation threshold and establishing deadenylation as the basis of BTG2-dependent quiescence [#26]. In parallel, BTG2 is a regulatory partner of the arginine methyltransferase PRMT1, modulating its activity to direct histone H4 arginine methylation at the RARβ promoter, to methylate Mre11 in support of double-strand break repair, and to methylate CDK4 and thereby block CDK4-Cyclin D3 assembly and cell-cycle progression [#0, #11, #16, #25]. BTG2 is transcriptionally induced by p53 after DNA damage and by NF-κB, and it imposes G1 arrest by suppressing cyclin E, CDK4, and cyclin D1 and G2/M arrest by inhibiting cyclin B1-CDK1 and disrupting the FoxM1-cyclin B1 loop [#1, #3, #8, #9, #14]. It additionally couples to differentiation and tissue patterning by enhancing BMP/Smad signaling, regulating adult neurogenesis through Id3 and Cxcl3, and modulating antioxidant responses via NFE2L2; in cancer it suppresses invasion through an Akt1-Sp1-Nox4-ROS axis [#7, #18, #21, #23, #32]. BTG2 protein stability is set by ubiquitin ligases SKP2 and TRIM6 (the latter targeting Lys5) and by Erk1/2 phosphorylation at Ser147 that recruits Pin1 to drive mitochondrial depolarization and senescence [#10, #17, #19, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing BTG2/TIS21 as a rapidly synthesized, rapidly turned-over soluble intracellular protein framed it as an immediate-response factor rather than a secreted or membrane signaling molecule.\",\n      \"evidence\": \"Pulse-chase metabolic labeling, subcellular fractionation, and immunohistochemistry\",\n      \"pmids\": [\"8263025\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define molecular function\", \"Reported as non-nuclear, later studies place it on chromatin and in deadenylation complexes\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of BTG2 as a p53-induced gene that arrests proliferation, and as a physical modulator of PRMT1 methyltransferase activity, defined its two foundational axes: the DNA-damage response and arginine methylation.\",\n      \"evidence\": \"p53-inducible gene identification with overexpression readouts; yeast two-hybrid, GST pulldown, and in vitro methyltransferase assays\",\n      \"pmids\": [\"8944033\", \"8663146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PRMT1 modulation connects to antiproliferation not yet defined\", \"Substrate specificity of the BTG2-PRMT1 module unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapping the conserved Box B domain interaction with mCaf1 placed BTG2 in the CCR4 deadenylase complex, while overexpression linked it to downregulation of cyclin E and CDK4 during G1 arrest.\",\n      \"evidence\": \"Yeast two-hybrid, GST pulldown, Co-IP, Box B deletion mutagenesis; stable transfection with FACS and cyclin/CDK kinase assays\",\n      \"pmids\": [\"9712883\", \"9766435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of Caf1 binding not yet tested\", \"Whether cyclin/CDK loss is direct or via mRNA decay unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating BTG2 binding to hCAF1/hPOP2 and to PICK1, with LXXLL-dependent modulation of ERα transcription, expanded its role to nuclear-receptor transcriptional control and PKC signaling.\",\n      \"evidence\": \"Co-IP, GST pulldown, domain mapping, ERα reporter assays; PICK1 PDZ-domain mapping and in vitro PKC phosphorylation\",\n      \"pmids\": [\"11136725\", \"11237868\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of PICK1 interaction not established\", \"Link between deadenylation complex binding and transcriptional output unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showing BTG2 resides in multiple CCR4-NOT complexes of distinct sizes that vary with cell-cycle stage suggested complex composition tunes BTG2 function across the cycle.\",\n      \"evidence\": \"Immunoprecipitation, gel filtration chromatography, and cell-cycle fractionation\",\n      \"pmids\": [\"12771185\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional difference between complex sizes not demonstrated\", \"Mechanism linking hCAF1 relocalization to function unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Three studies extended BTG2 to developmental and stress signaling: it binds BMP-Smad1/8 to enhance BMP signaling (with a vertebral phenotype in knockouts), is induced by NF-κB to suppress cyclin D1, and inhibits cyclin B1-Cdc2 via a PKCδ pathway independent of p53.\",\n      \"evidence\": \"Btg2-null mice with Co-IP and BMP reporters; NF-κB stimulation with cyclin D1 rescue; PKC pharmacology, nocodazole synchronization, and in vivo kinase assays\",\n      \"pmids\": [\"15542835\", \"15378000\", \"15302583\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Smad and cyclin effects share a common biochemical mechanism unresolved\", \"Direct versus indirect control of cyclin levels not separated from mRNA decay activity\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery that Erk1/2 phosphorylates BTG2 at Ser147 to recruit Pin1 and trigger mitochondrial depolarization defined a post-translational switch converting BTG2 toward cell death.\",\n      \"evidence\": \"In vitro kinase assay, P148A mutagenesis, Co-IP, shRNA, confocal Pin1 imaging, and JC-1 flow cytometry\",\n      \"pmids\": [\"15788397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How cytoplasmic Pin1 relocalization causes depolarization not detailed\", \"Relationship to deadenylation function unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"ChIP evidence that BTG2 brings PRMT1 to the RARα complex and deposits H4 arginine methylation at the RARβ promoter, reversed by retinoic acid, gave a concrete chromatin mechanism for BTG2 in differentiation priming.\",\n      \"evidence\": \"Co-IP of RARα complex, ChIP for H4 methylation/acetylation, and differentiation assays in myeloid progenitors\",\n      \"pmids\": [\"16782888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide scope of BTG2-directed H4 methylation unknown\", \"How retinoic acid triggers BTG2/PRMT1 dissociation unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"A cluster of studies cemented BTG2 as a general deadenylation activator and stability-regulated cell-cycle brake: it stimulates CAF1/CCR4-dependent poly(A) shortening of all transcripts, its crystal structure reveals the CAF1-binding interface, it inhibits FoxM1 by reducing cyclin B1-CDK1 activity, SKP2 targets it for degradation, and its PRMT1 partnership drives neurite outgrowth.\",\n      \"evidence\": \"In vitro deadenylation with CAF1 nuclease-dead mutants; X-ray crystallography with interface mutagenesis; in vitro kinase/FoxM1 mutant analysis with KO MEFs; Co-IP, ubiquitination and CHX-chase; PRMT1/Btg2 knockdown in Neuro2a\",\n      \"pmids\": [\"18337750\", \"18974182\", \"18393292\", \"19615363\", \"18773938\", \"18556508\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether deadenylation accounts for all antiproliferative phenotypes not fully separated from methylation activity\", \"In vivo target transcripts of BTG2-driven decay not enumerated at this stage\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"BTG2 was shown to promote DSB repair via PRMT1-dependent Mre11 methylation while damping ATM-Chk2-p53(S20) signaling, to drive p53-independent senescence through Pin1, and to control adult neurogenesis through direct repression of Id3.\",\n      \"evidence\": \"γH2AX/Comet assays with Mre11 methylation and phospho-signaling; senescence assays with Pin1 Co-IP and rescue; PC3/Tis21-null mice with ChIP at Id3 and behavioral readouts\",\n      \"pmids\": [\"23089312\", \"20569234\", \"20020054\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BTG2 simultaneously promotes repair and limits damage signaling mechanistically unresolved\", \"Pin1-dependent senescence versus DNA-repair roles not reconciled\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"BTG2 was linked to oxidative-stress defense through direct NFE2L2/Nrf2 interaction and antioxidant gene induction, to EMT suppression via miR-21-regulated prostate phenotype, and to Cxcl3-dependent cerebellar precursor migration and tumor suppression.\",\n      \"evidence\": \"Co-IP, ChIP at ARE, H2O2 viability with Box B mutagenesis; 3'-UTR decoy with orthotopic model; Tis21/Ptch1 double-KO with Cxcl3 rescue\",\n      \"pmids\": [\"22493435\", \"22614007\", \"23115191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether antioxidant and decay functions are coupled unknown\", \"Direct versus indirect nature of Cxcl3 regulation not fully resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Structural-functional reconstitution showed the BTG2 APRO domain bridges PABPC1 RRM1 to CAF1 sufficiently to stimulate deadenylation and to control proliferation, and BTG2 was shown to restrain cardiomyocyte hypertrophy by lowering cytosolic RNA via deadenylation-complex binding.\",\n      \"evidence\": \"In vitro reconstitution with purified domains and interface mutagenesis plus proliferation assays; cardiomyocyte shRNA with single-cell RNA imaging and mass spectrometry of partners\",\n      \"pmids\": [\"26912148\", \"27346836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the proliferation-relevant decay substrates not defined\", \"How PABPC1 bridging selects target mRNAs unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of PRMT1-mediated CDK4 methylation as the mechanism by which the BTG2-PRMT1 module blocks CDK4-Cyclin D3 assembly provided a direct biochemical link from arginine methylation to cell-cycle arrest in pre-B cells.\",\n      \"evidence\": \"Co-IP, in vitro CDK4 methylation assay, CDK4-Cyclin D3 pulldown, conditional KO pre-B cells, and BCR-ABL1 transformation model in vivo\",\n      \"pmids\": [\"28628091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDK4 methylation contributes to BTG2 function outside pre-B cells unknown\", \"Relationship to deadenylation-driven cyclin loss not integrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genetic dissection in T cells established that BTG1/2-driven mRNA deadenylation maintains lymphocyte quiescence, and TRIM6 was identified as an E3 ligase ubiquitinating BTG2 at Lys5 to control its stability.\",\n      \"evidence\": \"Conditional double-KO mice with mRNA-seq, poly(A) tail and half-life measurements; IP/proteomics with TRIM6 C15A mutant, Lys5 mutagenesis, and CHX-chase\",\n      \"pmids\": [\"32165587\", \"31992359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific quiescence-determining transcripts not enumerated\", \"Signals regulating TRIM6-BTG2 turnover unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"BTG2 mRNA was shown to be controlled by m6A modification: VIRMA/KIAA1429-deposited m6A reduces BTG2 mRNA via YTHDF2-dependent decay, defining an upstream layer of BTG2 regulation.\",\n      \"evidence\": \"MeRIP-seq, RNA stability assay, KIAA1429 knockdown, and m6A dot blot\",\n      \"pmids\": [\"35730068\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab correlation; direct YTHDF2 binding to BTG2 m6A sites not fully mapped\", \"Physiological contexts where this regulation operates limited\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"BTG2 was shown to bind Smad3 specifically and drive podocyte EMT in a TGF-β/Smad3-BTG2 feedback circuit, with podocyte-specific deletion protecting against glomerulosclerosis, extending BTG2's Smad-modulating role to disease.\",\n      \"evidence\": \"Podocyte-specific conditional KO, Co-IP discriminating Smad2 versus Smad3, SIS3 rescue, and ADR-induced FSGS model\",\n      \"pmids\": [\"37749872\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How BTG2 distinguishes Smad3 from Smad2 mechanistically unknown\", \"Reconciliation with earlier BMP-Smad1/8 enhancement not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BTG2 selects specific mRNAs for deadenylation versus broadly activating decay, and how its deadenylation and PRMT1-methylation activities are coordinated within a single antiproliferative program, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No defined transcript-selection rule for BTG2-driven decay\", \"No unified model linking deadenylation, arginine methylation, and transcriptional co-regulation\", \"Structural basis of context-specific Smad and nuclear-receptor partnering not solved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 12, 13, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [11, 18, 21]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [24, 7, 30]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [12, 26, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [31, 12]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [11, 18, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [12, 24, 26]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [3, 8, 9, 14, 25]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [1, 16]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [11, 18, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 30, 23]}\n    ],\n    \"complexes\": [\"CCR4-NOT deadenylase complex\"],\n    \"partners\": [\"PRMT1\", \"CNOT7\", \"PABPC1\", \"SMAD1\", \"SMAD3\", \"PIN1\", \"SKP2\", \"NFE2L2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}